What is the recommended management for Parkinson's disease, including pharmacologic and non‑pharmacologic treatments?

Parkinson's Disease Management

For newly diagnosed Parkinson's disease patients, initiate levodopa as first-line therapy in patients over 60 years old, while dopamine agonists or MAO-B inhibitors can be considered first in younger patients (<60 years) to delay motor complications, though levodopa remains the most effective symptomatic treatment at all disease stages 1, 2.

Initial Pharmacologic Management

Age-Based Treatment Algorithm

Patients ≥60 years old:

• Start with levodopa/carbidopa or levodopa/benserazide immediately
• Most effective medication for motor symptoms (tremor, rigidity, bradykinesia)
• No evidence of neurotoxicity to substantia nigra 3
• Superior efficacy outweighs concerns about future motor complications in this age group

Patients <60 years old:

• Consider starting with MAO-B inhibitors, dopamine agonists, or amantadine
• Delays levodopa-related motor complications (dyskinesias, motor fluctuations)
• Add levodopa when symptoms become inadequately controlled
• Goal: maintain Hoehn and Yahr Stage ≤2.0 (bilateral symptoms with preserved postural reflexes) 3

Specific Clinical Scenarios

Tremor-predominant disease:

• Anticholinergics or beta-blockers may be initiated first
• Particularly effective when tremor is the only or most prominent symptom 2

Mild symptoms only:

• MAO-B inhibitors alone may suffice initially
• Provides modest symptomatic benefit with good tolerability 2

Management of Motor Complications

Motor Fluctuations ("Off" Periods)

When patients develop wearing-off or unpredictable off-periods despite optimized levodopa:

1. Modify levodopa regimen first:

   • Increase dosing frequency
   • Reduce individual dose size while increasing frequency
   • No long-term advantage of controlled-release over standard formulations 3

2. Add adjunctive medications:

   • MAO-B inhibitors (rasagiline, selegiline)
   • COMT inhibitors (entacapone, opicapone)
   • Dopamine agonists (pramipexole, ropinirole, rotigotine)
   • All have Level I evidence for reducing off-time 2

Dyskinesias

Levodopa-induced dyskinesias:

• Reduce individual levodopa doses
• Increase dosing frequency
• Add amantadine (most effective anti-dyskinesia agent)
• Consider advanced therapies if refractory

Advanced Therapies for Complicated Disease

When patients develop medication-resistant symptoms, severe motor fluctuations, or disabling dyskinesias despite optimized oral therapy, advanced interventions should be considered 4.

Deep Brain Stimulation (DBS)

Strongest evidence-based advanced therapy:

• Subthalamic nucleus (STN-DBS): 5 RCTs demonstrate large improvements in motor impairment, fluctuations, and dyskinesia
• Sustained effectiveness beyond 15 years post-intervention
• Allows significant levodopa dose reduction
• Globus pallidus interna (GPi-DBS): Equally effective to STN for motor symptoms over 3 years
• Better for dyskinesia control but minimal levodopa reduction possible
• Target selection should be individualized by treatment center 4

Patient selection criteria:

• Age <70 years
• Non-demented
• Previous good levodopa response
• Medically unresponsive fluctuations 3

Early DBS consideration:

• Emerging evidence supports DBS in patients with beginning fluctuations (EarlyStim)
• Shows benefit before advanced complications develop 4

Continuous Infusion Therapies

Levodopa-carbidopa intestinal gel (LCIG):

• Two RCTs show moderate increase in on-time without troublesome dyskinesia
• Moderate decrease in daily off-time versus optimized oral therapy
• Sustained effects documented up to 3 years in open-label studies
• Consider when oral medications inadequate but patient not DBS candidate 4

Continuous apomorphine infusion (CAI):

• One RCT demonstrates moderate improvement in on-time without troublesome dyskinesia
• 12-week double-blind phase with 52-week open-label extension
• Alternative to LCIG or DBS 4

Non-Motor Symptom Management

Cognitive Impairment

• Cholinesterase inhibitors (rivastigmine, donepezil) for PD dementia
• Evidence-based benefit for cognitive symptoms 2
• Neuropsychological assessment should use PD-specific toolkit 5

Depression

• SSRIs or SNRIs as first-line pharmacotherapy
• Pramipexole (dopamine agonist) has specific antidepressant evidence in PD
• Cognitive-behavioral therapy effective, especially combined with pharmacotherapy
• rTMS shows promise as adjunctive treatment
• ECT reserved for severe, refractory cases 6

Psychosis/Hallucinations

• Clozapine has strongest evidence (Level I) for PD psychosis
• Requires regular blood monitoring
• Quetiapine commonly used but weaker evidence
• Pimavanserin (where available) is alternative 2

Autonomic Dysfunction

• Orthostatic hypotension: Fludrocortisone, midodrine, droxidopa
• Sialorrhea: Glycopyrrolate, botulinum toxin injections
• Constipation: Polyethylene glycol, increased fiber and fluids 2

REM Sleep Behavior Disorder

• Melatonin or clonazepam
• Often present as prodromal symptom 7

Non-Pharmacological Interventions

Exercise and physical therapy are essential components at all disease stages:

• Improves motor symptoms, balance, and quality of life
• Should be prescribed alongside pharmacotherapy, not as alternative
• Physiotherapy, occupational therapy, and speech therapy valuable in advanced stages 7, 8

Specific interventions:

• Cueing strategies for freezing of gait
• Dysphagia rehabilitation for swallowing difficulties
• Nutritional counseling to maintain weight
• Palliative care integration in advanced disease 8

Critical Pitfalls to Avoid

Impulse control disorders:

• Caused primarily by dopamine agonists
• Screen regularly for gambling, hypersexuality, compulsive shopping, binge eating
• Manage by reducing or withdrawing dopamine agonist, particularly in younger patients 2

Medication timing:

• Levodopa absorption impaired by dietary protein
• Advise taking 30-60 minutes before meals or 1 hour after

Anticholinergics in elderly:

• Avoid in patients >70 years due to cognitive side effects
• Increased fall risk 3

Delaying advanced therapies:

• Don't wait until patient is too debilitated
• DBS and infusion therapies most effective when patient still has good functional capacity
• Refer early when complications emerge despite optimization 4